The eŠect of incadronate, a third-generation bisphosphonate, was evaluated in rats with corticosteroid-induced osteopenia. Male Wistar rats were treated with methylprednisolone acetate (1 mg/kg, s.c.) once daily, 3 days a week for 12 weeks. Other groups received simultaneous treatment with methylprednisolone acetate and incadronate (0.03, 0.3 or 3 mg/kg, p.o.); incadronate was given once daily, 6 days a week for 12 weeks. Bone mineral densities (BMDs) of the second lumbar (L2) vertebra as well as the ultimate compressive strength of theˆfth lumbar (L5) vertebra decreased. Incadronate dose-dependently inhibited the loss of L2 BMDs and the decrease in strength of the L5 vertebrae. These results suggest that incadronate may be eŠective in treating osteopenia accompanying corticosteroid therapy.
INTRODUCTION
Corticosteroids are widely used to treat asthma, rheumatoid arthritis and many other in‰ammatory diseases due to their potent anti-in‰ammatory and immunosuppressive eŠects. It has been known for some time, however, that corticosteroids decrease bone formation by inhibiting osteoblast functions, 1) and that long-term corticosteroid treatment induces bone loss, which may lead to osteoporosis or pathologic fracture. 2) Bisphosphonates show clinical eŠec-tiveness in treating metabolic bone disorders such as Paget's disease, malignancy-associated hypercalcemia, tumor bone metastasis and osteoporosis. 3) Incadronate, a third-generation bisphosphonate, inhibits bone resorption more potently than etidronate, pamidronate or alendronate but does not cause calciˆcation disorders. 4 6) Incadronate prevents bone mineral density loss, furthermore, maintains the mechanical properties of bones in ovariectomized rats and dogs. 7 9) Its e‹cacy in treating corticosteroid-induced osteopenia was not been examined, however, rats with a corticosteroid-induced osteopenia model caused by treatment with methylprednisolone acetate were therefore used to evaluate the e‹cacy of incadronate in maintaining bone mineral density and mechanical properties.
MATERIALS AND METHODS

Experimental Animals
Male Sprague-Dawley rats (aged 13 weeks, weight 410 470 g) purchased from Charles River Japan Ltd. (Kanagawa) were used. All the rats were housed in group cages at a temperature of 23±3°C and a relative humidity of 55±15 ％ with a 13 h: 11 h light: dark cycle. The rats were fed standard rat chow containing 1.14％ calcium and 1.06％ phosphorous (CE-2; Japan Clea Co., Ltd.; Tokyo) and were given water ad libitum.
Drugs
Incadronate (lot No. K1759514) was synthesized by Yamanouchi Pharmaceutical Co., Ltd. Methylprednisolone acetate (Depo-Medrol ) was purchased from Upjohn Japan Pharmaceutical Co., Ltd. (Tokyo). Incadronate (0.03, 0.3 and 3 mg/ kg) was dissolved and diluted with distilled water to a volume of 5 ml/kg body weight. Methylprednisolone acetate (1 mg/kg) was suspended and diluted with saline containing 0.5％ methylcellulose to a volume of 2 ml/kg.
Experimental Design
Sixty rats were divided into 6 groups comprising 10 animals per group. On the day of the start of dosing, the rats in 1 of the 6 groups were sacriˆced as a pre-dosing group to provide pre-dosing data. The remaining 5 groups were treated for 12 weeks with one of the following: 1) saline containing 0.5％ methylcellulose＋distilled water (control group); 2) methylprednisolone acetate＋dis-tilled water (vehicle group); 3) methylprednisolone acetate＋incadronate 0.03 mg/kg (0.03 mg/kg incadronate group); 4) methylprednisolone acetate＋ incadronate 0.3 mg/kg (0.3 mg/kg incadronate group); or 5) methylprednisolone acetate＋incadro-nate 3 mg/kg (3 mg/kg incadronate group) for 12 weeks. Saline and methylprednisolone acetate were administered subcutaneously once daily 3 times a week for 12 weeks. Distilled water and incadronate were given orally once daily 6 times a week for 12 weeks.
Specimen Collection
On the day after thê nal dosing, all the rats were weighed and anesthetized with ether, and killed by blood letting from the abdominal aorta. Theˆrst to the sixth lumbar (L1-6) vertebrae were removed and separated into L1-3, L4, L5 and L6 vertebrae. The L1-3 vertebrae were immersed in 70％ ethanol after they were trimmed of the surrounding soft tissues. The L4, L5 and L6 vertebrae were wrapped separately in saline-soaked gauze without trimming of the surrounding soft tissues and stored at -30°C.
Measurements Bone Mineral Density of the L2 Vertebrae
The L2 vertebrae were separated from the L1-3 vertebrae and trimmed of any remaining surrounding soft tissue. The vertebrae were placed, spinous process up, in individual polystyrene containersˆlled with 70％ ethanol to a depth of 2 cm. The bone mineral density (BMD) was measured by dual energy X-ray absorptiometry (QDR2000; Hologic Inc.; Waltham, MA, USA).
Mechanical Strength of the L5 Vertebral Body Frozen L5 vertebrae were thawed at room temperature, and the remaining surrounding soft tissue was removed. All processes were removed with a diamond cutting disc. The vertebral body was then cut with a diamond disc such that the cut ends were parallel approximately 4.0 mm apart. After the anteroposterior length of the vertebral body was measured, the samples were placed centrally on the smooth surface of a steel disk (2.5 cm diameter) attached to a bone strength tester (TK-252C; Muromachi Kikai Co., Ltd.; Tokyo), and the craniocaudal compression load was applied to the specimen with a steel disk (1.5 cm diameter) at a nominal deformation rate of 2.5 mm/ min. The ultimate compressive strength (N) and structural stiŠness (N/mm) were obtained from the load-deformation curve.
Statistical Analysis
The measured values are expressed as the mean±the standard error. Preand post-treatment comparisons were made in the pre-dosing and control groups, and the eŠect of methylprednisolone was evaluated by comparing the control and vehicle groups. Student's t-test was used for these comparisons between two groups. The eŠect of incadronate was evaluated by Dunnett's multiple comparison test using the vehicle group as the control.
RESULTS
General Condition of the Animals
One animal died during the dosing period in each of the incadronate 0.03 and 0.3 mg/kg groups. No death occurred, however in the incadronate 3 mg/kg group. The absence of dose-dependence suggests that the deaths were caused not by the drug but by an error during administration. At necropsy, the body weight of the control group (631±14 g) was signiˆcantly higher than that of the pre-dosing group (466±6 g). Administration of methylprednisolone signiˆcantly inhibited weight gain as compared with the control group. There was no signiˆcant diŠerence in body weight at necropsy, however, between methylprednisolone-treated animals receiving either vehicle (454 ±7 g) or incadronate (0.03 mg/kg: 466±6 g, 0.3 mg /kg: 472±8 g, and 3 mg/kg: 440±9 g, respectively).
Bone Mineral Density
The L2 vertebral BMD in the control group (0.253±0.004 g/cm 2 ) was signiˆcantly higher than that in the pre-dosing group (0.215±0.002 g/cm 2 ). Administration of methylprednisolone for 12 weeks signiˆcantly reduced L2 vertebral bone mineral density compared with the control group. Incadronate resulted in a dose-dependent inhibition of BMD loss in the L2 vertebra, with a signiˆcant eŠect observed at doses of 0.3 mg/kg or higher ( Table 1) .
3. Mechanical Strength of the L5 Vertebrae The ultimate compressive strength of the L5 vertebra was signiˆcantly higher in the control group (533±24 N) than in the pre-dosing group (374±11 N). Administration of methylprednisolone for 12 weeks signiˆcantly reduced the ultimate compressive strength of the L5 vertebra compared with the control group. Incadronate inhibited this decrease dose-dependently, with a signiˆcant eŠect observed at a dose of 3 mg/ kg. Structural stiŠness did not diŠer signiˆcantly among the groups ( Table 2) . 
DISCUSSION
Corticosteroids are used to treat many disorders because of their potent anti-in‰ammatory and immunosuppressive eŠects. Secondary osteoporosis commonly occurs in patients treated with steroids at high doses or for long periods, however, presenting a major clinical problem for steroid treatment. This corticosteroid-induced osteoporosis is thought to result from decreased bone mineral content caused by increased bone resorption and reduced bone formation. Bone loss is due to two factor: a decline in osteoblast functions caused by the direct action of corticosteroids, which inhibit osteoblast diŠerentiation and proliferation, and increased bone resorption associated with secondary hyperparathyroidism, which caused by increased PTH secretion due to a negative calcium balance resulting from inhibition of calcium absorption from the intestine and reduced calcium resorption in the uriniferous tubules. The results of in vivo studies in animals do not show these eŠects clearly, however. In rats, both positive and negative eŠects on bone mineral balance, mechanical properties, and morphology have been reported. 10 12) Comparisons of these and related results are complicated by diŠer-ences in rat strain, sex, age, diet, steroid formulation, dose level and rate, and route or duration of administration. Nakamuta et al. 13) have shown that treatment with 1 mg/kg of methylprednisolone three times a week for two weeks decreased the levels of metabolic markers associated with bone formation and resorption without adversely aŠecting the general condition. The duration of administration was, however, insu‹cient to induce bone loss. In this study, therefore, treatment with 1 mg/kg of methylprednisolone three times a week for 12 weeks was selected as an appropriate dose to induce osteopenia. Although administration of methylprednisolone at a dose of 1 mg /kg inhibited weight gain, no weight loss or morbid outlook was observed. Furthermore, the L2 vertebral BMD and L5 vertebral ultimate compressive strength were higher in the vehicle group, moreover, than in the pre-dosing group. These results suggest that these reduction of BMD and compressive strength did not result from growth inhibition due to methylprednisolone.
The loss of bone mass that occurs in corticosteroidinduced osteoporosis is PTH-dependent, and the acceleration of bone resorption is thought to be caused by excess PTH secretion due to hyperparathyroidism. 14, 15) In the present study, the vehicle group given methylprednisolone at a dose of 1 mg/kg had a higher serum PTH level (22.7 pg/ml vs 15.7 pg/ml) and signiˆcantly lower L2 vertebral BMD than the control group, suggesting that administration of methylprednisolone at a dose of 1 mg/kg induced osteoporosis by causing mild secondary hyperparathyroidism.
Incadronate signiˆcantly inhibited the reduction of L2 vertebral BMD. Methylprednisolone also signiˆcantly reduced the ultimate compressive strength of the L5 vertebra. This partially explains why longterm corticosteroid use leads to increased susceptibility to vertebral compression fractures accompanying osteoporosis. Incadronate also dose-dependently inhibits the reduction in ultimate compressive strength caused by methylprednisolone. Corticosteroids have a more pronounced eŠect on trabecular bone than on cortical bone due to the higher turnover rate of the former. 16) Incadronate probably increased the BMD and bone strength of the lumbar vertebrae, therefore, by inhibiting the loss of trabecular bone mass caused by administration of corticosteroids.
In summary, the results show that incadronate inhibited reduction in BMD and bone strength in rats with steroid-induced osteopenia, suggesting that incadronate has promise as an eŠective therapeutic drug for treating corticosteroid-induced osteoporosis.
